Pfizer, Inc. CEO Albert Bourla said on Tuesday that the U.S. pharmaceutical industry should work more collaboratively with ...

Pfizer is backed by strong H1 results, a promising pipeline, improved financials, and solid valuation with long-term growth ...

Pfizer's stock has been struggling for multiple years, and even a low valuation hasn't made it an enticing option for many investors.

By stepping out as the first biopharma to win a three-year exemption from President Donald Trump’s earlier-announced plans for 100% tariffs, in return for agreeing to manufacture more of its drugs in ...

A pair of pharmaceutical giants spearheaded gains for other stocks in the industry on Tuesday, Sept. 30, 2025, while a new ...

President Trump and Pfizer are set to unveil a new website for Americans today, and lower medication costs. What is it? What ...

AstraZeneca's shares jumped after Pfizer's announcement of a major deal with the Trump administration. Pfizer's good news could benefit AstraZeneca, too. Pfizer CEO Albert Bourla appeared with ...

Pfizer CEO Albert Bourla noted in a statement from the drugmaker ... Shares of Pfizer Inc. climbed 38 cents to $24.40 before markets opened Monday while Metsera’s stock advanced about 61%.

Meanwhile, Pfizer offers one of the best dividends in the entire healthcare sector (and the entire market, for that matter).

Pfizer signed a deal with the White House to help Americans pay lower prices for prescription drugs. This agreement removes the uncertainty hanging over Pfizer's head related to the Trump ...